Stockscreener 앱 받기
18.24
1.66%
0.29
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma Announces Grants of Inducement Awards | Associated Press | syndication news - Enidnews.com
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CBIO: CR-001 and ADC pipeline aim for best-in-class oncology therapies, with pivotal data expected from 2027 - TradingView
HC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
[Form 4] CRESCENT BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01 - Stock Titan
Crescent Biopharma director granted 11,050 options | CBIO Insider Trading - Stock Titan
Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares - Stock Titan
Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan
Crescent Biopharma shareholders back directors, pay and auditor - TipRanks
Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay - Stock Titan
Crescent Biopharma, Inc. to Present at Jefferies and Goldman Sachs Healthcare Conferences in June 2026 - Quiver Quantitative
Crescent Biopharma to Present at June Investor Conferences - GlobeNewswire
CBIO: Directors elected, auditor ratified, and executive compensation approved with annual advisory votes - TradingView
CBIO: All proposals, including director elections and auditor ratification, were approved - TradingView
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS) - The Globe and Mail
Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Crescent Biopharma Rings the Closing Bell - Nasdaq
Crescent Biopharma downgraded by H.C. Wainwright - Quantisnow
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral By Investing.com - Investing.com South Africa
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral - Investing.com
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Decline Risk - newsline.com
Crescent Biopharma (CBIO) Edges Lower, Holds Near Key Support LevelBlock Trade Flow - The Legal Advocate
CBIO Q1 2026 Earnings: EPS Beat on Lower Net Loss as Pipeline AdvancesEarnings Forecast Report - newsline.com
Crescent Biopharma (CBIO) Surges 4.59% as Biotech Sector Gains MomentumWMA Signal - The Legal Advocate
Crescent Biopharma (CBIO) Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerFree Cash Flow Trends - The Legal Advocate
CBIO Q1 2026 Earnings: Narrowed Loss Beat Estimates as Clinical Pipeline AdvancesDownward Estimate Revision - newsline.com
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
CBIO Q1 2026 Earnings: Narrower Loss Surprises, Pipeline Progress ContinuesDividend Growth Analysis - Newser
Crescent Biopharma Inc. (CBIO) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDividend Cut Risk - Newser
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Sahm
CBIO Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline ProgressesSegment Revenue Breakdown - The Legal Advocate
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser
1.79%
자본화:
|
볼륨(24시간):